Castle Biosciences reported a pivotal quarter highlighted by the launch of AdvanceAD-Tx, a first-in-class gene expression test aimed at improving treatment outcomes for patients with moderate to severe atopic dermatitis.
- Successfully launched AdvanceAD-Tx, targeting a $33 billion market opportunity in the U.S. for moderate to severe atopic dermatitis.
- Clinical validation shows AdvanceAD-Tx can significantly improve treatment response rates for patients on JAK inhibitors versus traditional therapies.
- Approximately 80% of surveyed clinicians indicated intent to use AdvanceAD-Tx, underscoring strong market receptivity.
- The company plans to explore multiple reimbursement pathways to facilitate patient access and drive early adoption of the test.
Community Discussion